Evidence map›Paper›PMID 20133951›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2010

Insulin-like growth factors are more effective than progastrin in reversing proapoptotic effects of curcumin: critical role of p38MAPK.

Pomila Singh, Shubhashish Sarkar, Shahid Umar, William Rengifo-Cam, Amar P Singh, Thomas G Wood

Abstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Epigenetic regulation of humanStem cell investigation · 2016
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Pomila SinghDept. of Neuroscience and Cell Biology, Univ. of Texas Medical Branch, 10.104 Medical Research Bldg., 301 Univ. Blvd., Route 1043, Galveston, TX 77555-1043, USA. posingh@utmb.edu
Shubhashish Sarkar
Shahid Umar
William Rengifo-Cam
Amar P Singh
Thomas G Wood
The University of Texas Medical Branch at Galveston · US

Funding

Role of Annexin-II in growth factor/co-carcinogenic effects of progastrinR01CA097959 · NCI · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI SINGH, POMILA · 2003 to 2015
$3.7M
Growth Factors, Curcumin and Colon CarcinogenesisR01CA114264 · NCI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SINGH, POMILA · 2006 to 2010
$1.3M
Beta-Catenin/NF-kB in Hyperplasia/Neoplasia of Colonic Crypts: ChemopreventionR01CA131413 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI UMAR, SHAHID · 2008 to 2011
$1.2M
NCI NIH HHS R01CA097959NCI NIH HHS R01CA114264NCI NIH HHS R01CA131413
6 · The paper itself

Abstract

Progastrin and insulin-like growth factors (IGFs) stimulate hyperproliferation of intestinal epithelial cells (IECs) via endocrine/paracrine routes; hyperproliferation is a known risk factor for colon carcinogenesis. In the present study, inhibitory potency of curcumin in the presence or absence of progastrin and/or IGF-II was examined. Progastrin and IGF-II significantly increased proliferation of an immortalized IEC cell line, IEC-18, whereas curcumin decreased the proliferation in a dose-dependent manner. IGF-II was significantly more effective than progastrin in reversing antiproliferative effects of curcumin and reversed proapoptotic effects of curcumin by >80%; progastrin was relatively ineffective toward reversing proapoptotic effects of curcumin. IEC-18 clones were generated to overexpress either progastrin (IEC-PG) or hIGF-II (IEC-IGF). Proliferation of IEC-PG and IEC-IGF clones was increased, compared with that of control clones. Curcumin significantly reduced proliferation of IEC-PG, but not IEC-IGF, clones. Similarly, a human colon cancer cell line, Caco-2 (which expresses autocrine IGF-II), was relatively resistant to inhibitory effects of curcumin. However, Caco-2 cells treated with anti-IGF-II-antibodies were rendered sensitive to inhibitory effects of curcumin. Significant differences in inhibitory potency of curcumin against PG- vs. IGF-II-stimulated growth of IEC-18 cells were not reflected by differences in curcumin-mediated inhibition of activated (phosphorylated) ERKs/IKK(alpha/beta)/p65NF-kappaB and c-Src in wild-type (wt)IEC-18 cells, in response to the two growth factors. Surprisingly, curcumin was almost ineffective in reducing IGF-II-stimulated activation of p38MAPK but significantly reduced progastrin-stimulated phosphorylation of p38. Treatment with a p38MAPK inhibitor resulted in loss of protective effects of IGF-II against inhibitory effects of curcumin. These novel findings suggest that growth factor profile of patients and tumors may dictate inhibitory potency of curcumin and that combination of curcumin + p38MAPK inhibitor may be required for reducing hyperproliferative or tumorigenic response of IECs to endocrine and autocrine IGFs.

Indexed as

AnimalsAntibodiesApoptosisAutocrine CommunicationCaco-2 CellsCamptothecinCaspase 3Caspase 9Cell LineCell ProliferationCSK Tyrosine-Protein KinaseCurcuminEpithelial CellsGastrinsHumansI-kappa B KinaseAntibodiesbig gastrinCamptothecinCaspase 3Caspase 9CSK protein, humanCSK Tyrosine-Protein KinaseCurcuminGastrinsI-kappa B KinaseImidazolesInsulin-Like Growth Factor IIMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3NF-kappa Bp38 Mitogen-Activated Protein KinasesProtein Kinase InhibitorsProtein PrecursorsProtein-Tyrosine KinasesPyridinesSB 203580Somatomedinssrc-Family KinasesTranscription Factor RelA

Identifiers

PMID20133951
PMCPMC2853304
OpenAlexW2058646369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.